Solvonis Therapeutics plc (LON:SVNS)

Market Cap	4.02M
Revenue (ttm)	347.00K
Net Income (ttm)	-2.62M
Shares Out	2.30B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,548,948
Average Volume	8,772,294
Open	0.175
Previous Close	0.175
Day's Range	0.170 - 0.178
52-Week Range	0.100 - 1.407
Beta	1.70
RSI	42.44
Earnings Date	Apr 25, 2025

About Solvonis Therapeutics

Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous poly...

• Industry: Plastics Materials, Synthetic Resins, and Nonvulcanizable Elastomers
• Founded: 2017
• Employees: 7
• Stock Exchange: London Stock Exchange
• Ticker Symbol: SVNS

Financial Performance

In 2023, Solvonis Therapeutics's revenue was 587,000, an increase of 8.30% compared to the previous year's 542,000. Losses were -3.12 million, 15.3% more than in 2022.